Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples
AIDSPublished 1 June 2000
Kurt Hertogs, Stuart Bloor, Sharon D. Kemp, Christel Van den Eynde, Timothy M. Alcorn, Rudi Pauwels
Citations184
SJR quartileQ1
SJR score1.21
SNIP0.90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Extensive use of first-generation PIs leads to the emergence of HIV-1 isolates possessing cross-resistance to all members of this class, and identifying particular mutational profiles among these isolates may assist in the design of new generation inhibitors with specific activity against protease-mutant HIV strains.
Abstract
Extensive use of first-generation PIs leads to the emergence of HIV-1 isolates possessing cross-resistance to all members of this class. Identification of particular mutational profiles among these isolates may assist in the design of new generation inhibitors with specific activity against protease-mutant HIV strains.
Keywords
Immunology and MicrobiologyMedicine
JAMAAntiretroviral Therapy for HIV Infection in 1998
1,016 Citations1998Charles C. J. Carpenter, Margaret A. Fischl +12 more
Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection, and increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection.
NatureIn vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
979 Citations1995Jon H. Condra, William A. Schleif +14 more
Five resistant variants isolated from patients undergoing therapy with the protease inhibitor MK-639 exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors, suggesting that com-bination therapy with multiple protease inhibition may not prevent loss of antiviral activity resulting from resistance selection.
Nature MedicineOrdered accumulation of mutations in HIV protease confers resistance to ritonavir
766 Citations1996Akhteruzzaman Molla, Marina Korneyeva +15 more
Analysis of the HIV protease gene from the plasma of HIV–infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitors ritonavir, suggesting that dual protease inhibitor therapy might increase the duration of viral suppression.
Journal of VirologyGenetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
405 Citations1996Jon H. Condra, Daniel Holder +21 more
The evolution of this resistance to IDV was found to be cumulative, indicating the need for ongoing viral replication in this process and strongly suggest that therapy should be initiated with the most efficacious regimen available, both to suppress viral spread and to inhibit the replication that is required for the evolution of resistance.
Antimicrobial Agents and ChemotherapyA Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs
391 Citations1998Kurt Hertogs, Marie‐Pierre de Béthune +15 more
A new method for high-throughput analysis of clinical samples that permits the simultaneous detection of HIV type 1 (HIV-1) phenotypic resistance to both RT and PR inhibitors by means of recombinant virus assay technology is described.
AIDS Research and Human RetrovirusesThe HIV-1 Protease as a Therapeutic Target for AIDS
341 Citations1992Christine Debouck
This review summarizes the strategies and multidisciplinary efforts that have been applied to date to the identification of specific inhibitors of this critical viral enzyme, including rationally designed peptide substrate analogs, compounds conceived from tertiary structure information on the enzyme and natural products.
Journal of VirologyDrug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
323 Citations1997Y M Zhang, Hiromi Imamichi +5 more
This is the first report of the emergence of mutations in the gag p7/p1 protease cleavage sites in patients receiving protease therapy and identifies this change as an important determinant of HIV-1 resistance to protease inhibitors in patient populations.
New England Journal of MedicineThe Molecular Biology of Human Immunodeficiency Virus Type 1 Infection
272 Citations1991Warner C. Greene, Franklin H. Epstein +1 more
The magnitude of the mounting AIDS problem is indeed sobering; between 1 and 2 million Americans are now infected, and nearly half the patients have died as a result of their disease.
Antimicrobial Agents and ChemotherapyAntiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
209 Citations1996Amy K. Patick, Hongmei Mo +9 more
The potent anti-HIV activity of AG1343 against several isolates suggests thatAG1343 should perform well during ongoing human phase II clinical trials.
Antimicrobial Agents and ChemotherapyRecombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
204 Citations1994Paul Kellam, Brendan Larder
The recombinant virus assay can be performed in approximately 3 weeks without the use of donor PBLs and therefore represents a rapid, nonselective procedure for the assay of clinical isolates.
Antimicrobial Agents and ChemotherapyGenotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir
203 Citations1998Amy K. Patick, M. Duran +8 more
Analysis of protease genes from plasma HIV type 1 (HIV-1) RNA revealed a unique aspartic acid (D)-to-asparagine (N) substitution at residue 30 (D30N) and suggested that individuals failing short courses of nelfinavir-containing regimens may respond to regimens containing other protease inhibitors.
Annals of Internal MedicineMultiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients
199 Citations1998Robert W. Shafer, Mark A. Winters +2 more
This study examined isolates from four heavily treated patients with HIV-1 infection who had started receiving antiretroviral therapy before potent three-drug combinations were available and had not achieved plasma HIV-2 RNA suppression despite treatment with several combination regimens, reasoning that they were at risk for developing HIV- 1 strains resistant to each of the drugs they had received.
Antimicrobial Agents and ChemotherapyResistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors
194 Citations1998Daniel Boden, Martin Markowitz
The emergence of drug resistance complicating anti-human immunodeficiency virus type 1 (HIV-1) therapy remains a significant limitation in the clinical utility of inhibitors directed against specific HIV enzymatic targets.
AIDSBaseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
118 Citations1999P. Richard Harrigan, Kurt Hertogs +9 more
Baseline resistance to ritonavir or saquinvir or both was associated with a poor antiviral response, and the measurement of drug resistance may assist in optimizing antiretroviral therapy in the clinic.
AIDSThe antiviral effect of ritonavir and saquinavir incombination amongst HIV-infected adults
54 Citations1998Stephanie A. Rhone, Robert S. Hogg +6 more
It is demonstrated that a ritonavir and saquinavir-based combination can produce a substantial decrease in plasma viral load with half of the participants decreasing their plasma viral Load to below the limit of quantification of the assay.
Journal of Antimicrobial ChemotherapyEmergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir
33 Citations1997K. J. IVES, Helmut Jacobsen +6 more
The phenotypic and genotypic properties of virus from the peripheral blood mononuclear cells (PBMC) and plasma of eight HIV-1-infected asymptomatic patients before and during monotherapy with the proteinase inhibitor saquinavir suggest the presence of virus resistant to saquinvir in vivo.
Expert Opinion on Investigational DrugsThe role of combinations of HIV protease inhibitors in the management of persons with HIV infection
22 Citations1998Graeme Moyle
Concerns regarding disturbances in fat metabolism, lipodystrophy and glucose intolerance remain obstacles to the widespread use of these regimens as initial therapy, and limited resistance data are available from dual PI failures.